Lung Cancer Dispatch
Follow
Find tag "NY-ESO-1"
3.8K views | +2 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

New Cancer Vaccine Approach Directly Targets Dendritic Cells

New Cancer Vaccine Approach Directly Targets Dendritic Cells | Lung Cancer Dispatch | Scoop.it

"Celldex Therapeutics announced today that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published inScience Translational Medicine. The data demonstrate robust antibody and T cell responses and evidence of clinical benefit in patients with very advanced cancers and suggest that CDX-1401 may predispose patients to better outcomes on subsequent therapy with checkpoint inhibitors. CDX-1401 is an off-the-shelf vaccine consisting of a fully human monoclonal antibody with specificity for the dendritic cell receptor DEC-205 linked to the NY-ESO-1 tumor antigen. The vaccine is designed to activate the patient's immune system against cancers that express the tumor marker NY-ESO-1. While the function of NY-ESO-1 continues to be explored, references in the literature suggest that its expression might reflect the acquisition of properties that cancers find useful, such as immortality, self-renewal, migratory ability and the capacity to invade."


Editor's note: Cancer vaccines like CDX-1401 are a type of immunotherapy, meaning that they boost a patient's own immune system to fight cancer. CDX-1401 is able to attack tumor cells because the tumor cells have a molecule called NY-ESO-1 that CDX-1401 recognizes. We recently published a story about another treatment that is meant for patients whose tumors have NY-ESO-1. To learn more about how patients can use molecular testing to see if particular treatments might work for them, click here.

Cancer Commons's insight:

Medical Xpress  |  Apr 16, 2014

more...
Rescooped by Cancer Commons from Melanoma Dispatch
Scoop.it!

Using a Person's Own Immune System to Fight Cancer: Phase I Clinical Trial of New Immunotherapy Beginning

Using a Person's Own Immune System to Fight Cancer: Phase I Clinical Trial of New Immunotherapy Beginning | Lung Cancer Dispatch | Scoop.it

"Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites."


Editor's note: This treatment looks for and targets cells that have the protein NY-ESO-1. Only 10-15% of tumors have NY-ESO-1, and patients' tumors must test positive for NY-ESO-1 in order for the patients to enroll in the trial. Learn more about immunotherapy and clinical trials here.

Cancer Commons's insight:

ScienceDaily  |  Apr 10, 2014

more...
Cancer Commons's curator insight, April 10, 3:08 PM

ScienceDaily  |  Apr 10, 2014

Cancer Commons's curator insight, April 10, 3:09 PM

ScienceDaily  |  Apr 10, 2014